

SLLK, Control Peptide for TSP1 Inhibitor

Catalog No: tcsc7050



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



Specifications

CAS No:

464924-27-4

Formula:

$C_{21}H_{41}N_5O_6$

Pathway:

Others

Target:

Others

Purity / Grade:

>98%

Solubility:

H2O

Observed Molecular Weight:

459.58

Product Description

SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine). Sequence: Ser-Leu-Leu-Lys.

In Vivo: TGF- β 1 is significantly lower (0.10 ± 0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice

receiving SLLK control peptide at day 42 (0.20 ± 0.02 pg/mL; $P=0.0001$). mRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides^[1]. Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice^[2].



SLLK

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!